Anchor Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-85,186
Closed -$15.7M – 245
2024
Q4
$15.7M Sell
85,186
-15,484
-15% -$2.98M 0.45% 81
2024
Q3
$19.8M Sell
100,670
-792
-0.8% -$165K 0.53% 68
2024
Q2
$21M Sell
101,462
-4,599
-4% -$1.04M 0.59% 62
2024
Q1
$28.7M Sell
106,061
-5,841
-5% -$1.39M 0.75% 53
2023
Q4
$26.5M Sell
111,902
-7,372
-6% -$1.45M 0.7% 53
2023
Q3
$23.4M Sell
119,274
-5,308
-4% -$1.09M 0.65% 53
2023
Q2
$26.2M Buy
+124,582
New +$24.8M 0.68% 54

Other funds holding CRL

Anchor Capital Advisors's CRL Position: Q1 2025 in Review

Anchor Capital Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 85,186 shares — an estimated $15.7M sold.

Anchor Capital Advisors first reported a position in CRL in Q2 2023 and held it in 7 quarters. The position peaked at $28.7M in Q1 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Anchor Capital Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Anchor Capital Advisors sold 85,186 Charles River Laboratories shares in Q1 2025, an estimated $15.7M.
  • Anchor Capital Advisors first reported a position in Charles River Laboratories in Q2 2023 and held it in 7 quarters.
  • Anchor Capital Advisors's Charles River Laboratories position peaked at $28.7M in Q1 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Anchor Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.